![]() Further, the globalization of healthcare practices and standards has opened up opportunities for such players even in the developing markets of the world. In terms of geography, more than 75% of the contract manufacturers engaged in the production of antibodies are based in North America or Europe.ĬMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities in order to enhance their core competenciesĬontract service providers are known to either invest in expanding their existing infrastructure and constructing new facilities or acquiring the facilities of other industry stakeholders in order to accommodate the growth in this respective business. This indicates that stakeholders are actively striving to adopt the one stop shop model and provide end to end services to customers worldwide. In addition, more than 55% have the capabilities to manufacture antibodies at all scales of operation. It is worth mentioning that small ( less than 51 employees) and mid-sized firms collectively capture more than 70% of the total dataset.Īmong the players that have expertise in antibody contract manufacturing, majority of the antibody contract manufacturers were established during the period 1980 to 2010. The antibody contract manufacturing market is presently dominated by the presence of mid-sized companies ( between 51 to 500 employees). Several companies worldwide claim to possess the required expertise and infrastructure to offer contract manufacturing services for a variety of antibody-based productsĬurrently, over 100 industry players are actively involved in the antibody production. ![]() Historical and prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing. Under the terms of the agreement, Samsung Biologics is responsible for large-scale manufacturing of monoclonal antibodies against SARS-CoV-2. It is worth highlighting that, in April 2020, Vir Biotechnology signed a USD 362 million contract manufacturing agreement with Samsung Biologics. In order to combat the COVID-19 infection, drug developers and researchers are exploring different ways to develop antibody treatments that are more potent and safer to quell the novel coronavirus. Further, owing to legacy challenges associated with the development and production of biologics, such as advanced supply chain requirements, outsourcing antibody production operations is a popular trend. This trend is unlikely to change in the near future as advanced variants, such as bispecific antibodies and antibody fragments-based products, are steadily gaining traction. ![]() Owing to their high specificity and the favorable safety profile associated with the therapeutic use of such molecules, antibody-based interventions presently constitute the largest class of biologics in the industry. It is worth noting that, till date, more than 100 therapeutic monoclonal antibodies have been approved across different geographies. In fact, several experts consider monoclonal antibodies to be the backbone of the biopharmaceutical industry. Since the approval of Orthoclone OKT3® in 1986, monoclonal antibodies have become an important part of modern healthcare practices. In fact, CMOs engaged in this domain are actively collaborating with other players and expanding their existing capabilities and capacities in order to cater to the overall demand for therapeutic antibodies. This can be attributed to the fact that employing such third-party service providers offers various advantages, such as reduction in overall production cost and decrease in time to market. This trend is also gaining popularity within the antibody therapeutics market, as developers are increasingly outsourcing their antibody production requirements to contract service providers. In recent years, contract manufacturers have become an integral part of the overall biopharmaceutical market.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |